7xm asia login register

7xm asia login register The holidays are a magical time for kids, filled with decorations, celebrations and a break from school. But during the fun and festivities, parents must remember that this season can also bring an increased risk to children’s safety. Amid all the activities and family gatherings, children may face an environment where the risk of abuse quietly rises. As a survivor of child sexual abuse and a mother myself, I can personally attest that this should be a concern for parents across all zip codes, races, religions and socioeconomic backgrounds. With 42 million survivors of sexual abuse in America, it is clear this danger does not discriminate. The good news, however, is that we can prevent future abuse by educating ourselves and our children about personal safety. As uncomfortable as it is to acknowledge, 90% of child abuse is perpetrated by someone the child — and their parents — know and trust. With many relatives, friends and neighbors visiting during the holidays, children are more likely to encounter someone who may take advantage of that access and increased commotion. And while it’s difficult to confront this issue, the sad reality is that one in nine girls and one in 20 boys experience sexual abuse before turning 18. However, there is hope. Studies show that 95% of child sexual abuse can be prevented through education and awareness. Empowering our children with knowledge about personal safety doesn’t need to be a scary experience. Instead, it can be woven into family values when teaching your kids about common life lessons, such as respect, boundaries and the power of using their voice. Regardless of your child’s age, starting a conversation about safety is essential and can be done in fun and engaging ways. Consider beginning with these simple but crucial steps before the holiday chaos sets in: For older children, parents can also discuss how predators may use manipulation tactics or technology to build trust and then violate it with unsafe secrets or touches. Encourage open conversation about their thoughts and feelings in different unsafe scenarios. Let’s give our kids the gift of safety this holiday season. Through open dialogue and intentional conversations, we can empower them with the tools to establish boundaries and understand consent. Resources such as the Safer, Smarter Families website offer free, personalized family safety plans based on your child’s age. Parents should also read up on the warning signs of potential abuse. Knowledge is power, and by educating ourselves on the signs of potential abuse, we can be more prepared to protect our children. This gift will protect them well beyond the holiday season. For more information on child abuse prevention, visit LaurensKids.org . Lauren Book is a child advocate, former classroom teacher, best-selling author, former Florida state Senator, and the founder and CEO of Lauren’s Kids. As a victim of childhood sexual abuse for six years at the hands of a trusted caretaker, Lauren founded Lauren’s Kids as a vehicle to prevent childhood sexual abuse and help other survivors heal.State and federal police will meet to determine whether firebomb attack on Adass Israel Synagogue a terrorism incidentROSEN, GLOBAL INVESTOR COUNSEL, Encourages Dentsply Sirona Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – XRAY

CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.The billing of London-born former Chelsea boss Hayes against England’s Dutch manager Sarina Wiegman – arguably the best two bosses in the women’s game – had generated more buzz in the build-up than the players on the pitch, despite it being a rare encounter between the two top-ranked sides in the world. Hayes enjoyed her return to familiar shores but felt the US lacked the “killer piece” after they looked the likelier side to make the breakthrough. Elite meeting of the minds 🌟 pic.twitter.com/R4d8EArqTp — U.S. Women's National Soccer Team (@USWNT) November 30, 2024 Asked what was going through her mind during the national anthem, Hayes said: “I was definitely mouthing (it), and Naomi (Girma) and Lynn (Williams) could see that I was struggling with where to be and all that. “I got to the end of the anthems and I thought, ‘that’s so ridiculous. I’m proud to be English and I’m proud of our national anthem, and I’m also really proud to coach America’. “Two things are possible all at once. I don’t want to fuel a nationalist debate around it. The realities are both countries are really dear to me for lots of reasons, and I’m really proud to represent both of them.” The Lionesses did not register a shot on target in the first half but grew into the game in the second. US captain Lindsey Horan had the ball in the net after the break but the flag was up, while Hayes’ side had a penalty award for a handball reversed after a VAR check determined substitute Yazmeen Ryan’s shot hit Alex Greenwood’s chest. Hayes, who left Chelsea after 12 trophy-packed years this summer, said: “I’ve been privileged to coach a lot of top-level games, including here, so there’s a familiarity to being here for me. “It’s not new to me, and because of that there was a whole sense of I’m coming back to a place I know. I have a really healthy perspective, and I want to have a really healthy perspective on my profession. “I give everything I possibly can for a team that I really, really enjoy coaching, and I thrive, not just under pressure, but I like these opportunities, I like being in these situations. They bring out the best in me. “You’ve got two top teams now, Sarina is an amazing coach, I thought it was a good tactical match-up, and I just enjoy coaching a high-level football match, to be honest with you. I don’t think too much about it.” Hayes had travelled to London without her entire Olympic gold medal-winning ‘Triple Espresso’ forward line of Trinity Rodman, Mallory Swanson and Sophia Smith, all nursing niggling injuries. Before the match, the 48-year-old was spotted chatting with Wiegman and her US men’s counterpart, fellow ex-Chelsea boss Mauricio Pochettino, who was also in attendance. England were also missing a number of key attackers for the friendly including Lauren Hemp, Lauren James and Ella Toone, all ruled out with injury. "This shows where we are at and we need to keep improving. It is November now. This is good but we want to be better again. We have to be better again." 👊 Reaction from the boss ⬇️ — Lionesses (@Lionesses) November 30, 2024 Wiegman brushed aside suggestions from some pundits that her side were content to settle for a draw. She said: “I think we were really defending as a team, very strong. We got momentum in the second half, we did better, and of course both teams went for the win. “So many things happened in this game, also in front of the goal, so I don’t think it was boring. “We wanted to go for the win, but it was such a high-intensity game, you have to deal with a very good opponent, so you can’t just say, ‘Now we’re going to go and score that goal’. “We tried, of course, to do that. We didn’t slow down to keep it 0-0. I think that was just how the game went.”

Digital IDs revolutionize the future of travel: A seamless holiday experience awaitsCARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.

Larson Financial Group LLC Grows Holdings in Howmet Aerospace Inc. (NYSE:HWM)When Carl Sagan was five years old, his mother enrolled him at the local library. He would walk there on his own, asking the librarian questions that his parents couldn't answer, such as, “What are stars?” Reflecting on the experience later, he recounted: “I went to the librarian and asked for a book about stars [...] and the answer was stunning. It was that the Sun was a star, but really close. The stars were suns, but so far away they were just little points of light. The scale of the universe suddenly opened up to me. It was a kind of religious experience. There was a magnificence to it, a grandeur, a scale which has never left me. Never ever left me.” This anecdote, shared by Kay Davidson in one of several biographies written about Sagan, illustrates one of his most compelling traits: an insatiable curiosity. Over time, this was complemented by intellectual prowess, skepticism, a passion for teaching and making science accessible to the public, and a notable ego. Together, these qualities made him one of the most influential and fascinating figures in space exploration during the latter half of the 20th century. 4 View gallery An insatiable curiosity. High school student Carl Sagan, 1951 ( Photo: Wikipedia ) "It just grabbed me" Carl Edward Sagan was born on November 9, 1934, in Brooklyn, New York, to a Jewish family. His father, a textile worker, had immigrated from Ukraine, and his mother, a homemaker, was born in New York. The family lived modestly and later moved to New Jersey due to his father's work. . Carl inherited his mother’s intellectual curiosity and skeptical outlook, while his father instilled in him an immense curiosity and sense of wonder about the world. From a young age, Sagan channeled these traits into a deep passion for science. In a biography by Ray Spangenburg, Sagan described his parents’ influence as follows: "My parents were not scientists. They knew almost nothing about science. But in introducing me simultaneously to skepticism and to wonder, they taught me the two uneasily cohabiting modes of thought that are central to the scientific method." Sagan was an outstanding student from a young age. While his teachers recognized his potential and sought to support him, his parents couldn’t afford private education for gifted students. He taught himself many subjects, including chemistry, but his primary scientific focus was space. At age 12, when his grandfather asked what he wanted to do when he grew up, Carl replied, “An astronomer,” to which his grandfather responded, “Fine, but how will you make a living?” Later, upon discovering that astronomers could indeed earn a living doing what they loved, Sagan knew he would pursue the field. ''I didn't make a decision to pursue astronomy,'' he would later say. ''Rather, it just grabbed me, and I had no thought of escaping.'' He graduated from high school at just 16 years old. According to another biographer, William Poundstone, near the end of high school, he entered a competition with an essay speculating on the potential dangers of encountering extraterrestrial life. He speculated that such a meeting could be devastating for humanity, much like the catastrophic effects that the encounter with European civilization brought upon the Indigenous peoples of the Americas. This essay may have been influenced by young Sagan's love for science fiction. Sagan received a full scholarship to the University of Chicago, where he began studying physics in 1951. He went on to earn a master’s degree and later a Ph.D. in astronomy, which he completed in 1960. His doctoral research, supervised by astronomer Gerard Kuiper, focused on the physical properties of planets and moons. At the time, new measurements showed that the surface of Venus was extremely hot, contrary to earlier assumptions that it might have Earth-like temperatures. In his dissertation, Sagan proposed that the greenhouse effect was responsible for Venus’s high temperatures, demonstrating that carbon dioxide and water vapor were the primary culprits. He later published these findings in a significant paper in Science. During his studies, Sagan collaborated with several renowned scientists, including George Gamow, a physicist who was instrumental in developing the Big Bang theory. The origin of life was another topic that had fascinated Sagan since childhood. As a student, he worked with renowned chemist Harold Urey, who led the seminal experiment exploring the chemical origins of life on Earth, and with geneticist Joshua Lederberg, a pioneer of gene therapy. Sagan also spent summers training with Hermann Muller, a geneticist and zoologist at Indiana University, who studied the effects of radiation and strongly opposed nuclear weapons. 4 View gallery These images were captured thanks to Sagan’s efforts to persuade NASA leaders to photograph Earth from afar. The planets of the solar system, photographed by Voyager 1 in 1990 ( Photo: NASA ) At the University of Chicago, Sagan met Lynn Margulis, a brilliant young scientist four years his junior who had entered the university at just 14. They married in 1957 when Margulis was 19. The marriage lasted seven years and produced two children. Margulis went on to have a distinguished scientific career, becoming one of the foremost researchers in evolutionary biology. New frontiers After earning his doctorate, Carl Sagan pursued further training at the University of California, Berkeley, where he chose to study biology to deepen his understanding of topics related to the potential development of life on other planets. At the same time, he joined the scientific team for NASA's Mariner 2 mission, a spacecraft launched to explore Venus. In 1963, Sagan became a researcher at Harvard University, where he continued his studies of the planets of the solar system. Among his accomplishments was developing a model of Mars's atmosphere, which demonstrated that its seasonal changes were driven by dust storms. He also joined the scientific teams for additional space missions, including Mariner 9, the first spacecraft to orbit Mars, whose findings helped validate Sagan’s prediction. 4 View gallery Designed to convey a message from humanity to intelligent extraterrestrials. The plaque sent aboard the Pioneer 10 and Pioneer 11 spacecraft ( Photo: Wikipedia ) Sagan’s extensive research on the planets and his fascination with origin of life research led him to repeatedly explore whether life could develop elsewhere in the solar system and under what conditions. For example, he explored the possibility for life in Venus’s atmosphere and the formation of relatively complex molecules within the environments of planets like Jupiter. These studies positioned Sagan as a founding figure in two scientific fields that were once peripheral to astronomy: planetary science, which focuses on processes occurring on planets, moons, and other celestial bodies, and exobiology—now commonly known as astrobiology—which focuses on the conditions necessary for life and the potential for its emergence or presence in other planetary systems. In 1966, Sagan co-authored Intelligent Life in the Universe with Soviet astronomer Iosif Shklovsky, earning him public recognition beyond the scientific community. The following year, he published a detailed article on the subject in National Geographic and appeared on several television programs. By this point, it was clear that Sagan aimed for a career that would bring him broad public recognition and allow him to present scientific work to a wider audience. This approach was unconventional in academia at the time, and some of his colleagues at Harvard viewed it as a compromise of scientific integrity in favor of self-promotion and publicity. According to his former student David Morrison, this perception likely contributed to Harvard’s decision not to grant Sagan tenure in 1968, despite his prolific research and reputation as a beloved and respected lecturer. Consequently, Sagan had to seek employment elsewhere. Unlike Harvard, Cornell University in upstate New York was eager to recruit faculty researchers with a potential for stardom. In 1969, Sagan joined Cornell, making it his academic home. A star in the scientific sky Carl Sagan remained a leading figure in planetary science and a regular contributor to solar system exploration missions. Notably, he was part of the scientific team for the Viking Mars landers, playing a crucial role in selecting their landing sites in 1976. He also contributed to the Pioneer 10 and Pioneer 11 missions, which became the first spacecraft to cross the asteroid belt and study Jupiter up close. Sagan further contributed to the Voyager missions, designed to explore the outer planets, and the Galileo mission, which studied Jupiter and its atmosphere. His research drew heavily on data from these missions, including analysis of the geology of Mars at Viking landing sites, studying the composition of Jupiter’s clouds, and investigating the processes of formation of organic compounds in Titan’s atmosphere, Saturn's largest moon. Sagan didn’t just study the possibility of extraterrestrial life—he was also among the first to propose practical methods for communicating with potential alien civilizations. He suggested adding a small metal plaque to the Pioneer spacecraft, featuring a brief description of humanity, illustrations of humans, and a cosmic map indicating Earth’s location. Designed to remain in space long after the spacecraft completed their missions, these plaques were intended to be discovered by intelligent extraterrestrial beings. The artwork for the plaque was created by Sagan’s second wife, artist Linda Salzman, whom he married in 1968. Together, they had one child. During this period, Sagan emerged as an increasingly prominent public figure and a science ambassador in popular media. He achieved this partly through his popular science books. One of his most successful works was The Cosmic Connection, published in 1973, in which he extensively explored the possibility of extraterrestrial life. At the same time, Sagan did not shy away from addressing popular claims made by alien enthusiasts, who asserted that intelligent extraterrestrials frequently visit Earth and that governments are concealing the evidence. Sagan strongly advocated for a scientific approach to evaluating such reports. The success of The Cosmic Connection led to Sagan becoming a regular guest on The Tonight Show, where he often showcased new images from space missions he was involved in. Despite his busy schedule, he always made time to fly to California for interviews with Johnny Carson, whom he referred to as hosting "the largest classroom in history." Sagan’s eloquent media appearances turned him into a true celebrity. His work and image graced the covers of major magazines like Time and Newsweek. His public recognition soared to new heights in 1978 when his next bestseller, The Dragons of Eden: Speculations on the Evolution of Human Intelligence, won the Pulitzer Prize for General Non-Fiction. The cosmos, television, and everything By the late 1970s, following the successful Viking landings on Mars and with the Voyager spacecraft en route to Jupiter, Carl Sagan set out to use television to bring science to the broadest audience possible. He established his own production company, raised approximately a million dollars from investors, and began developing a script for a documentary series about the universe and humanity’s understanding of it. The series, Cosmos, consisted of 13 hour-long episodes and aired in 1980 on the public television channel KCET. It was an enormous success, winning Emmy and Peabody Awards and reaching over 400 million viewers worldwide. The companion book, also titled Cosmos, remained on The New York Times bestseller list for more than a year. The success of the series and book officially cemented Sagan’s celebrity status, earned him widespread media attention and brought him significant financial success. This success came at a cost. While working on the series, Sagan neglected his academic responsibilities, canceled courses, and left research students - who had chosen Cornell specifically to work under his guidance - without supervision, forcing them to seek other advisors. This behavior drew significant criticism from colleagues, which escalated as fame brought its drawbacks, including harassing phone calls, death threats, and an influx of fans or eccentrics roaming the university grounds in search of him. While working on the production of Cosmos, Sagan fell deeply in love with Ann Druyan, who collaborated with him on its production and writing. Although he was still married at the time, Sagan moved to Los Angeles to live with Druyan during the series' production. In 1981, he divorced his second wife and married Druyan. The couple later had a daughter and a son. They continued to collaborate professionally, including co-authoring several books. Following the success of Cosmos, Sagan received a $2 million advance from the major publisher Simon & Schuster to write a novel about humanity’s first contact with extraterrestrial life. The resulting book, Contact, published in 1985, was another major success and was later adapted into a Hollywood film starring Jodie Foster in 1997. A pale blue dot Carl Sagan’s scientific work also explored the possibility of contact with extraterrestrial life. The Voyager spacecraft, launched in 1977, carried a more elaborate message about humanity than the Pioneer plaques. Attached to Voyager was a gold-plated copper record—a kind of "time capsule" of life on Earth. The record contained natural sounds such as ocean waves, music from various periods and cultures, voice greetings in dozens of languages, and images of life on Earth, all stored in audio form. Instructions for playing the record were etched onto its cover, based on the assumption that any extraterrestrial beings who might find it would have some ability to perceive and interpret visuals and sounds in ways similar to humans. Sagan chaired the committee that selected the content, with its artistic direction led by his new partner, Ann Druyan. The record also included an audio representation of Druyan's brainwaves. Sagan was also a strong supporter of SETI (Search for Extraterrestrial Intelligence), an initiative dedicated to scanning space for radio signals that might indicate the presence of intelligent alien civilizations. He collaborated with his colleague, astronomer Frank Drake, to design the Arecibo message—a radio signal broadcast into space with the aim of reaching extraterrestrial beings and drawing their attention to humanity's existence 4 View gallery Cosmic Love. Sagan with his third wife, Ann Druyan, who collaborated with him on the Cosmos series and co-authored several of his books ( Photo: Peter Morenus/Cornell University, Courtesy of Druyan-Sagan Associates, Inc. ) In 1990, after Voyager 1 completed its primary scientific mission in the solar system and began its journey outward into interstellar space, Sagan’s persistent efforts convinced NASA leadership to capture a distant photograph of Earth. The resulting image, taken from about six billion kilometers away, showed Earth as a tiny speck—less than a pixel—against the vast emptiness of space. This iconic image was named Pale Blue Dot by Sagan, a title that also became the theme of his 1994 book Pale Blue Dot: A Vision of the Human Future in Space, in which he reflected on humanity’s place in the cosmos and, above all, our smallness. “Think of the rivers of blood spilled by all those generals and emperors so that in glory and triumph they could become the momentary masters of a fraction of a dot,” Sagan said in a lecture at Cornell University. Years of disappointments In the 1980s, under U.S. President Ronald Reagan, the government increased defense spending and promoted the "Star Wars" initiative, a program aimed at deploying defense systems in space. This, along with the Soviet Union’s response, rekindled fears of nuclear war between the superpowers. Sagan, an opponent of nuclear weapons since his student days, co-authored an influential scientific paper with four colleagues on the potential effects of nuclear war. In this paper, they coined the term "nuclear winter," referring to climate changes caused by massive amounts of dust rising into the atmosphere following large-scale nuclear explosions. Sagan went on to co-author two books on the dangers of nuclear weapons and frequently discussed the topic in media interviews. However, unlike his work on space exploration, his stance on the politically sensitive issue of nuclear weapons drew significant opposition. Critics included those who viewed disarmament as a threat to U.S. security, as well as scientists who disputed the nuclear winter theory, arguing that it was an overly pessimistic and insufficiently substantiated prediction. This opposition sometimes manifested in personal attacks on Sagan in the media, a stark contrast to the favorable coverage he had previously enjoyed. Many believe that Sagan's advocacy and his efforts to highlight the dangers of war through the concept of nuclear winter ultimately helped pave the way for the disarmament negotiations and the eventual signing of the Intermediate-Range Nuclear Forces (INF) Treaty by U.S. and Soviet leaders in 1987. During this period, Sagan also faced challenges from budget cuts to U.S. space exploration, including NASA missions. The Challenger space shuttle disaster in 1986 marked a low point for the agency and disrupted research-oriented missions. Sagan saw this as an opportunity to promote U.S.-Soviet collaboration on a joint mission to Mars, leveraging the Soviet Union's growing openness to the West. However, these efforts were unsuccessful, and Sagan was forced to abandon the idea after the Soviet Union’s collapse, which left its space program in a state of limbo due to the political upheaval. In 1990, amid stalled space initiatives, Sagan made his most significant scientific misstep. Following Iraq’s invasion of Kuwait and its threats to ignite oil wells if the West intervened, Sagan feared that such widespread fires could release enough soot to trigger a smaller-scale version of nuclear winter. Despite opposition from three of his four co-authors of the original nuclear winter paper—who did not believe the fires would have a global climatic impact—Sagan published his predictions in articles and TV interviews. In early 1991, Iraqi forces did set Kuwait’s oil wells ablaze, but when the smoke cleared, it became evident that Sagan had been wrong. The fires did not cause global or even local climate changes. This miscalculation drew widespread criticism, and Sagan faced ridicule from his opponents, some of whom used the incident to cast doubt on the entire nuclear winter theory. In 1992, Sagan was nominated for membership in the National Academy of Sciences (NAS). Despite meeting the accepted criteria for scientific publications, contributions to the scientific community, and his efforts to make science accessible to the public, his nomination received only about half the votes—well below the two-thirds majority required. Two years later, the Academy awarded him its prestigious Public Welfare Medal in recognition of his contributions to popularizing science and explaining complex issues. However, it is unclear whether this honor softened the sting of his earlier rejection. Adding to his disappointment, the 1993 book Shadows of Forgotten Ancestors, co-authored with his wife Ann Druyan, did not achieve the success they had hoped for, despite being regarded by some critics as his best work. Billions and billions In 1994, Carl Sagan was diagnosed with cancer and began undergoing treatment. Despite his illness—or perhaps because of it—he did not slow down and continued working on new books. Foremost among them was The Demon-Haunted World: Science as a Candle in the Dark. This book was a passionate defense of science, the scientific method, and rational thinking, countering irrationality and pseudoscience. In the book, Sagan revisits his field of expertise, extraterrestrial communication, and critiques unfounded claims about alien visits to Earth and alleged abductions by extraterrestrial spacecraft. He also equips readers with a "baloney detection kit," a list of logical fallacies typical of pseudoscientific arguments. Additionally, Sagan used the book to publicly acknowledge his earlier error in predicting the catastrophic environmental effects from the burning of oil wells in Kuwait. Get the Ynetnews app on your smartphone: Google Play : https://bit.ly/4eJ37pE | Apple App Store : https://bit.ly/3ZL7iNv Another book Sagan managed to work on with Druyan was Billions and Billions: Thoughts on Life and Death at the Brink of the Millennium. The title, evoking the vast number of stars in the universe, became synonymous with Sagan since the days of Cosmos. In the book, Sagan and Druyan discuss the application of scientific tools to everyday life and global issues such as climate change and international relations. Sagan also shares his religious perspective, expressing skepticism about the existence of God in the traditional sense, though he refrains from identifying himself as an atheist. Sagan did not live to see the publication of this final book. After undergoing three bone marrow transplants, his condition deteriorated, and he passed away from pneumonia on December 20, 1996, at the age of 62. “Carl Sagan, more than any contemporary scientist I can think of, knew what it takes to stir passion within the public when it comes to the wonder and importance of science,” eulogized Bruce Alberts, president of the National Academy of Sciences. “American astronomy lost its clearest and most colorful voice with the death of Carl Sagan,” wrote astronomer Yervant Terzian of Cornell University. Quoting a Washington Post obituary by Joel Aschenbach that stated, “We have needed Sagan since Copernicus removed us from the center of the Universe,” Terzian added, “And the need remains. Carl Sagan received a great many awards during his 62 years, but ‘billions and billions’ would not have been enough to repay what the scientific community owes him.” Content distributed by the Davidson Institute of Science Education . >The berry that ate TikTok: Inside Australia’s $750m acai boom

Job market jitters real for some mid-career Minnesotans and recent grads

Robots are taking over multiple industries, easing tasks with greater accuracy while reducing the workload for humans. From warehouses to hospitals, robots are speeding tasks up more effectively. Now, Honda has unveiled a robot designed to provide support and companionship to children undergoing extended hospital stays. Called Haru, the AI-powered robot was introduced at the Virgen del Rocío University Hospital (HUVR) in Seville, Spain. Developed by Honda Research Institute Japan Co., Ltd. (HRI-JP), Haru was designed to be a social robot that makes people smile through expressive communication and forms empathetic relationships with people. As a compact desk-top robot with a total height of 30cm (12 inches), Haru can be placed on a table to engage in conversations with people. Haru obtains biometric information of users Honda explains that Haru obtains users’ biometric information , such as facial expressions and voice tones, through its built-in camera and microphones. This information is then analyzed to assess the user’s emotional state, enabling Haru to respond with appropriate empathy and emotional support. Moreover, Haru can also be linked to a wristwatch-type wearable sensor worn by the user, allowing for even more detailed analysis of the user’s conditions , according to the company. Honda maintains that as a robot, Haru does not have any human attributes, such as gender, race, or nationality, and is always capable of communicating from a neutral perspective. It enables the robot to effectively facilitate communication beyond generational and cultural differences, especially in group communication. Haru communicates with children HUVR has integrated Haru into its initiatives aimed at enhancing the well-being of children undergoing long-term cancer treatment. The robot has been assisting the hospital’s neuropsychologists in conducting emotional and cognitive assessments . Using AI technology, Haru communicates with children and assists neuropsychologists in conducting emotional and cognitive assessments. Due to the amount of time the assessment takes, there is a limit to the number of assessments the neuropsychologists can conduct each year: the number had been limited to 510 per year, including follow-up consultations until now. With the introduction of Haru, the number of assessments the hospital can conduct each year is expected to increase to as many as 4,500, according to a press release . Haru supports intellectual, physical rehabilitation programs The company maintains that Haru has been supporting intellectual and physical rehabilitation programs provided to young patients at the hospital. Haru learns the rehabilitation programs and can guide the children through the process while engaging them in conversation. The demonstration experiment showed that 95% of children were more actively engaged in rehabilitation while receiving guidance from Haru, compared to conventional human guides. “We have been conducting joint research with HRI-JP for several years now, and gained wonderful results. We have identified that Haru holds great potential in bringing happiness to children,” said Virgen del Rocío University Hospital in Seville (HUVR) in a statement. Typically, technologies used in hospitals focus on medical treatments or physical well-being. However, Haru demonstrates a unique ability to positively influence the psychological well-being of our young patients, contributing to a more positive atmosphere throughout the hospital. “The support that Haru provides, enabling children under hospital care to feel more happiness and connection with others, is unique only to Haru and offers valuable benefits not found in traditional medical care. We believe that Haru is a groundbreaking presence that creates an environment where young patients can enjoy their time here at our hospital,” added HUVR in a statement .

( MENAFN - GlobeNewsWire - Nasdaq) Guangzhou, China, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Youxin technology Ltd (the“Company” or“Youxin Technology”), a software as a service (“SaaS”) and platform as a service (“PaaS”) provider committed to helping retail enterprises digitally transform their businesses, today announced the pricing of its initial public offering (the“Offering”) of 2,300,000 Class A ordinary shares at a public offering price of US$4.50 per Class A ordinary share. The Class A ordinary shares have been approved for listing on The nasdaq Capital market and are expected to commence trading on December 20, 2024 under the ticker symbol“YAAS.” The Company expects to receive aggregate gross proceeds of US$10.35 million from the Offering, before deducting underwriting discounts and other related expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to 345,000 additional Class A ordinary shares at the public offering price, less underwriting discounts. The Offering is expected to close on or about December 23, 2024, subject to the satisfaction of customary closing conditions. Net proceeds from the Offering will be used for (i) research and development, including development of the Company's SaaS standard product and further investment in the Company's cloud services, (ii) investment in the Company's sales and marketing, including expanding distribution channels for existing and future market, and (iii) general corporate purposes, which may include capital expenditures, potential strategic investments and acquisitions. Aegis Capital Corp. is acting as the sole book-running manager for the Offering. Kaufman & Canoles P.C. is acting as the U.S. counsel to the Company, and Olshan Frome Wolosky LLP is acting as the U.S. counsel to Aegis Capital Corp. A registration statement on Form F-1 (File No. 333-274404) relating to the Offering was filed with the U.S. Securities and Exchange Commission (“SEC”) and was declared effective by the SEC on December 19, 2024. A final prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website at . The Offering is being made only by means of a prospectus, forming a part of the registration statement. Electronic copies of the final prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th Floor, New York, New York 10105, by email at ... , or by telephone at +1 (212) 813-1010. Interested parties should read in their entirety the prospectus and the other documents that the Company has filed or will file with the SEC, which provide more information about the Company and the Offering. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Youxin Technology Ltd Youxin Technology Ltd is a SaaS and PaaS provider committed to helping retail enterprises digitally transform their businesses using its cloud-based SaaS product and PaaS platform to develop, use and control business applications without the need to purchase complex IT infrastructure. Youxin Technology provides a customized, comprehensive, fast-deployment omnichannel digital solutions that unify all aspects of commerce with store innovations, distributed inventory management, cross-channel data integration, and a rich set of ecommerce capabilities that encompass mobile applications, social media, and web-based applications. The Company's products allow mid-tier brand retailers to use offline direct distribution to connect the management team, distributors, salespersons, stores, and end customers across systems, apps, and devices. This provides retailers with a comprehensive suite of tools to instantly address issues using real-time sales data. For more information, please visit the Company's website: . Cautionary Note Regarding Forward-Looking Statements The foregoing material may contain“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's expectations regarding the completion, timing and size of the proposed Offering and statements regarding the Company's product development and business prospects and the use of proceeds from the sale of the Company's shares in the Offering, and can be identified by the use of words such as“may,”“will,”“expect,”“project,”“estimate,”“anticipate,”“plan,”“believe,”“potential,”“should,”“continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results. For more information, please contact: Youxin Technology Ltd. Investor Relations Department Email: ...d Ascent Investor Relations LLC Tina Xiao Phone: +1-646-932-7242 Email: ... MENAFN19122024004107003653ID1109014586 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

KKR Real Estate Finance Trust Inc. ( NYSE:KREF – Get Free Report ) declared a quarterly dividend on Thursday, December 12th, NASDAQ Dividends reports. Stockholders of record on Tuesday, December 31st will be given a dividend of 0.25 per share on Wednesday, January 15th. This represents a $1.00 annualized dividend and a dividend yield of 9.73%. The ex-dividend date is Tuesday, December 31st. KKR Real Estate Finance Trust has a dividend payout ratio of 89.3% meaning its dividend is currently covered by earnings, but may not be in the future if the company’s earnings fall. Equities research analysts expect KKR Real Estate Finance Trust to earn $1.19 per share next year, which means the company should continue to be able to cover its $1.00 annual dividend with an expected future payout ratio of 84.0%. KKR Real Estate Finance Trust Price Performance NYSE KREF opened at $10.28 on Friday. The company has a debt-to-equity ratio of 3.75, a quick ratio of 277.63 and a current ratio of 277.63. The stock has a market cap of $715.21 million, a price-to-earnings ratio of -34.27 and a beta of 0.98. The business has a 50 day simple moving average of $11.40 and a 200 day simple moving average of $11.15. KKR Real Estate Finance Trust has a 52-week low of $8.71 and a 52-week high of $13.65. Analyst Ratings Changes Several research analysts have recently weighed in on the company. Raymond James reduced their price objective on KKR Real Estate Finance Trust from $14.00 to $13.50 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. lowered their price objective on shares of KKR Real Estate Finance Trust from $12.00 to $11.50 and set an “overweight” rating on the stock in a report on Monday, December 9th. Wells Fargo & Company increased their target price on shares of KKR Real Estate Finance Trust from $13.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. JMP Securities lifted their price target on shares of KKR Real Estate Finance Trust from $12.50 to $13.00 and gave the company a “market outperform” rating in a research note on Wednesday, October 30th. Finally, Keefe, Bruyette & Woods raised shares of KKR Real Estate Finance Trust from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $11.50 to $13.00 in a research report on Thursday, September 5th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, KKR Real Estate Finance Trust presently has an average rating of “Buy” and a consensus target price of $12.75. View Our Latest Analysis on KREF About KKR Real Estate Finance Trust ( Get Free Report ) KKR Real Estate Finance Trust Inc, a mortgage real estate investment trust, focuses primarily on originating and acquiring transitional senior loans secured by commercial real estate (CRE) assets. It engages in the origination and purchase of credit investments related to CRE, including leveraged and unleveraged commercial real estate loans. Further Reading Receive News & Ratings for KKR Real Estate Finance Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KKR Real Estate Finance Trust and related companies with MarketBeat.com's FREE daily email newsletter .Rob Pelinka executed a major move today, as he sent D'Angelo Russell and Maxwell Lewis, along with three second-round picks, to the Brooklyn Nets , in exchange for Dorian Finney-Smith and Shake Milton. With the deal now being official, Pelinka put out a statement thanking Russell and Lewis, along with sharing optimism and excitement for the new players coming in. “We want to thank D’Angelo for his second stint with us, where we celebrated some great moments and accomplishments on the court together. We want to wish him and Maxwell Lewis well in their future endeavors with the Brooklyn Nets." "With this trade, we are thrilled to add the physicality, toughness, and elite shooting that Dorian Finney-Smith will bring to our core. We also greatly value the playmaking of Shake Milton. We are excited for our fans to get both of these players out on the court.” Dorian Finney-Smith is a major get for the Lakers , as he adds great size, defense, and three-point shooting to the Lakers, three things that the team has struggled without this season. For the season, Finney-Smith is averaging 10.4 points, 4.6 rebounds, 1.6 assists, 1.6 steals, and 0.9 blocks, while shooting 45.9% from the field, 43.5% from deep (a career-high), and 62.5% from the free-throw line. As for Shake Milton, he has also played well in the limited minutes he has gotten this season, averaging 18.2 minutes, 7.4 points, 2.4 assists, 1.9 rebounds, and 0.6 steals per game, while shooting 46.5% from the field, 38.9% from deep, and 75.8% from the free-throw line. His strong three-point shooting is also set to give the Lakers a massive boost from range. The Lakers desperately needed a move like this, that gives them everything they're looking for right now. On top of that, with the way he had been playing, moving D'Angelo Russell had become a bit of a priority. His performances had been poor, and with his expiring contract, they risked losing him for no return whatsoever. The Lakers Must Make More Moves While Rob Pelinka did a good job with this deal, he must be active. As his former client and Los Angeles Lakers legend Kobe Bryant once said, 'Job's not finished'. Pelinka must go out and get more reinforcements if he is serious about helping the team achieve contender status. One of the crucial things to note about this deal is the fact that the Lakers didn't give up any of their first-round picks. They currently have their 2026, 2028, 2029, and 2030 first-round picks, which they can use to land another strong player and help improve the team going forward. It was reported this week that Pelinka wants to bring in young players who not only contribute at a high level right now but can be future stalwarts for JJ Redick when the team eventually moves on from LeBron James . Perhaps this is why the team refuses to include Austin Reaves in a potential deal for Zach LaVine . We had suggested a monster trade for the Lakers to land De'Aaron Fox just a few days ago. But with the departure of Russell, who was on a decent $18.7 million salary, that deal will be difficult to pull off. Regardless, expect the Lakers to be active on the trade front in the coming weeks, as we fast approach the February 6th deadline. This article first appeared on Fadeaway World and was syndicated with permission.Dexus ( OTCMKTS:DXSPF – Get Free Report ) shares shot up 3.5% during mid-day trading on Friday . The stock traded as high as $7.65 and last traded at $7.65. 6,500 shares changed hands during trading, an increase of 185% from the average session volume of 2,284 shares. The stock had previously closed at $7.39. Dexus Stock Up 3.5 % The stock’s 50 day moving average is $7.65 and its 200-day moving average is $7.65. About Dexus ( Get Free Report ) Dexus engages in real estate investments, leasing and tenant services. It operates its business through following segments: Office, Industrial, Property Management, Funds Management, Development & Trading, and Others. The Office segment offers domestic office space with any associated retail space, car parks and office developments. Read More Receive News & Ratings for Dexus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexus and related companies with MarketBeat.com's FREE daily email newsletter .